Iron
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Iron
- Iron: From Iron Products (No Labeled Indication on Record) to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia
Iron: From Iron Products (No Labeled Indication on Record) to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia
One-Sentence Summary
Iron is an essential mineral, and the US products on record are marketed without a documented approved indication. The TxGNN model predicts it may be effective for vitamin B12- and folate-independent constitutional megaloblastic anemia, but 0 clinical trials and 0 publications support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified (all listed US licenses have blank indication text) |
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this record. Iron is needed for hemoglobin synthesis and red blood cell production, and that is presumably why the model links it to anemia-related disease nodes.
That link is weak for this disease. Megaloblastic anemia is defined by impaired DNA synthesis in red cell precursors, not by a lack of iron. The “B12- and folate-independent” form is a rarer constitutional (inherited) group that does not respond to those vitamins. There is no established mechanism by which iron would correct it.
The very high score (99.89%) most likely reflects closeness to other anemia nodes in the knowledge graph rather than a real biological link. No trial or publication was retrieved to support it.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not listed | Ferrum Metallicum (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
| Not listed | Ferrum Metallicum (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
| Not listed | Ferrum metallicum (Boiron) | Pellet | Not stated |
| Not listed | Ferrum Sidereum 30X (True Botanica, LLC) | Liquid | Not stated |
| Not listed | Ferrum Metallicum (Hahnemann Laboratories, Inc.) | Pellet | Not stated |
These are 5 of 20 records. The listed products are homeopathic-style preparations, not iron replacement therapies with a labeled indication. Other dosage forms on record include tablet (soluble), gel, patch, ointment and globule.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trial or literature support and no plausible mechanism. The score likely comes from graph proximity to anemia in general. The US products on record carry no documented indication.
To proceed, the following is needed:
- A mechanistic rationale for iron in constitutional megaloblastic anemia, or confirmation that the model link is an artifact
- Mechanism of action data for iron, and the package insert warnings and contraindications
- Any case reports or clinical studies for this specific disease
- Alternative candidates in the same pack: Plummer-Vinson syndrome (rank 2) has 20 publications, all reviews and case reports, and iron repletion is the established management, so it is a supportive therapy rather than a novel repurposing. “Vitamin deficiency disorder” (rank 5) has iron-focused trials, including a Phase 2 IV iron study in heart failure with iron deficiency. Iron for iron deficiency is already standard of care. Both are better starting points than this prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.